WaveMan
WaveMan · Company
TEVA · Teva Pharmaceutical Industries Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

TEVA Teva Pharmaceutical Industries (TEVA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000818686
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
366
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $205.3K priced

What the filings say about TEVA

Insiders, 180 days
-$35.9M net sold
14 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$16.7M
5 notices

Teva Pharmaceutical Industries insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, TEVA PHARMACEUTICAL INDUSTRIES LTD insiders sold a net $35.9M of stock across 164 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
MIGNONE ROBERTO
Director
SELL
2026-09-22 SECtraded 2026-09-18
367,600
$14.4M
+3.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Dec 16, 2025.
  • 3 other insiders sold within 30 days.
  • 366 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MIGNONE ROBERTO sold about $14.4M of TEVA on Sep 18, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 366 funds added in the latest 13F quarter.
Savage Brian
Interim Chief Legal Officer
SELL
2026-09-22 SECtraded 2026-09-18
4,503
$174.2K
+3.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 5, 2026.
  • The trade is 39.7% of the 11,339 shares held after it.
  • 3 other insiders sold within 30 days.
  • 366 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Chief Legal Officer Savage Brian sold about $174.2K of TEVA on Sep 18, 2026; 3 other insiders sold within 30 days and 366 funds added in the latest 13F quarter.
Savage Brian
Interim Chief Legal Officer
SELL
2026-09-22 SECtraded 2026-09-18
2,525
$98.8K
+3.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 5, 2026.
  • The trade is 28.6% of the 8,814 shares held after it.
  • 3 other insiders sold within 30 days.
  • 366 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Chief Legal Officer Savage Brian sold about $98.8K of TEVA on Sep 18, 2026; 3 other insiders sold within 30 days and 366 funds added in the latest 13F quarter.
Savage Brian
Interim Chief Legal Officer
SELL
2026-09-22 SECtraded 2026-09-18
314
$12.2K
+3.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 5, 2026.
  • The trade is 3.7% of the 8,500 shares held after it.
  • 3 other insiders sold within 30 days.
  • 366 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Chief Legal Officer Savage Brian sold about $12.2K of TEVA on Sep 18, 2026; 3 other insiders sold within 30 days and 366 funds added in the latest 13F quarter.
Satchi-Fainaro Ronit
Director
SELL
2026-08-25 SECtraded 2026-08-21
415
$15.5K
+6.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.4% of the 111,986 shares held after it.
  • 7 other insiders sold within 30 days.
  • 366 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Satchi-Fainaro Ronit sold about $15.5K of TEVA on Aug 21, 2026; 7 other insiders sold within 30 days and 366 funds added in the latest 13F quarter.
164 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 159 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$35.9M over 180 days
-$17.0M over 90 days
below 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
366 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+4.3% year over year
more than 51% of Pharma & Biotech
Margin
8.2% net margin
more than 80% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.7% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
below 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TEVA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+112.4%12M
-0%+39%+79%+118%2025-102025-122026-022026-042026-062026-082026-10 2026-09-18 · MIGNONE ROBERTO sold $14.4M2026-03-03 · Francis Richard D sold $13.3M2026-02-26 · Kalif Eliyahu Sharon sold $11.6M2026-02-15 · Francis Richard D sold $9.8M2026-02-15 · Francis Richard D sold $5.5M2026-05-14 · Kalif Eliyahu Sharon sold $5.5M2026-05-01 · Sabag Mark sold $5.0M2025-11-06 · MIGNONE ROBERTO sold $4.8M2026-06-11 · Kalif Eliyahu Sharon sold $3.6M2025-12-09 · Sabag Mark sold $3.4M2025-12-09 · Daniell Richard sold $3.3M2025-12-09 · Sabag Mark sold $2.8M2025-12-16 · MIGNONE ROBERTO sold $2.3M2026-03-03 · Hughes Eric A sold $2.2M2026-03-03 · Daniell Richard sold $2.2M2026-03-03 · Daniell Richard sold $2.0M2026-03-17 · Sabag Mark sold $1.9M2025-11-26 · MIGNONE ROBERTO sold $1.3M2026-05-14 · Lippman Evan sold $1.3M2026-03-04 · Daniell Richard sold $1.2M2026-03-04 · Daniell Richard sold $1.1M2026-05-05 · Daniell Richard sold $1.1M2026-03-03 · Francis Richard D sold $1.0M2026-08-03 · Hughes Eric A sold $892.1K2026-03-04 · Francis Richard D sold $759.3K2025-11-14 · Fox Christine sold $753.3K2026-04-30 · Fox Christine sold $750.6K2025-11-20 · Fox Christine sold $699.5K2026-08-17 · Lippman Evan sold $680.3K2026-03-04 · Daniell Richard sold $664.2K2026-03-05 · Francis Richard D sold $634.2K2026-03-05 · Daniell Richard sold $547.7K2026-03-05 · Shields Matthew sold $547.7K2026-06-03 · Shields Matthew sold $532.3K2026-03-05 · Jover Placid sold $448.1K2026-08-03 · Jover Placid sold $447.4K2026-03-03 · Hughes Eric A sold $390.8K2026-05-06 · Weiss Amir sold $384.4K2025-12-16 · Weiss Amir sold $371.5K2026-03-04 · Hughes Eric A sold $366.1K2026-06-18 · Shields Matthew sold $321.5K2026-03-05 · Hughes Eric A sold $301.9K2026-09-21 · Savage Brian filed to sell $273.1K2026-09-18 · Bridger Management, LLC (1) filed to sell $14.4M2026-08-17 · Lippman Evan filed to sell $680.3K2026-08-03 · Hughes Eric A filed to sell $892.1K2026-08-03 · Jover Placid filed to sell $447.4K2026-06-18 · Shields Matthew filed to sell $321.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TEVA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
63,894,301 sh
$2.2B
Phoenix Financial Ltd.
42,933,367 sh
$1.5B
WCM INVESTMENT MANAGEMENT, LLC
41,315,232 sh
$1.4B
MENORA MIVTACHIM HOLDINGS LTD.
39,854,383 sh
$1.4B
Migdal Insurance & Financial Holdings Ltd.
38,922,212 sh
$1.3B

Congress trades in TEVA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TEVA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Savage Brian
Filed 2026-09-21
$273.1K
Bridger Management, LLC (1)
Filed 2026-09-18
$14.4M
Lippman Evan
Filed 2026-08-17
$680.3K
Hughes Eric A
Filed 2026-08-03
$892.1K
Jover Placid
Filed 2026-08-03
$447.4K

TEVA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares MSCI Israel ETF
$90.7M position · as of 2026-05-31
8.8%
VanEck Israel ETF
$10.6M position · as of 2026-06-30
6.9%
Upright Growth Fund
$2.2M position · as of 2026-06-30
6.7%
SOUND SHORE FUND
$43.0M position · as of 2026-06-30
4.3%
VistaShares Target 15 DRUKMacro Distribution ETF
$666.1K position · as of 2026-07-31
4.0%
Baron Health Care Fund
$4.4M position · as of 2026-06-30
3.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Richard Francis
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$15.5M
$40.9M
$5.6M
+128%
+18%
2023
$25.7M
$26.2M
$4.5M
+8%
+9%
2022
$15.5M
$17.2M
$4.0M
-5%
+8%
2021
$14.7M
$7.6M
$3.7M
-17%
+13%
2020
$15.7M
$10.9M
$4.0M
-2%
+14%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $35.9M sold by insiders over 180 days, 366 funds added last quarter, $16.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TEVA financials

Revenue growth
+4.3%
XBRL, annual
Net margin
8.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
4.30x
long-term 2017-12-31 (103 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.06x
TTM operating cash flow over long-term 2017-12-31 (103 months older than the period end) plus current 2026-06-30
Return on equity
+9.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+1.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+4.2%
operating income after a 1.7% effective tax rate, over long-term 2017-12-31 (103 months older than the period end) plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+6.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
67.32x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$76.7B
market value at close 2026-10-27 on 2026-06-30 shares, plus long-term 2017-12-31 (103 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+2.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$17.3B$16.5B$15.8B$14.9B
Gross profit$8.9B$8.1B$7.6B$7.0B
Operating income$2.2B-$303.0M$433.0M-$2.2B
Net income$1.4B-$1.6B-$559.0M-$2.4B
EPS (diluted)1.21-1.45-0.50-2.20
Operating cash flow$1.6B$1.2B$1.4B$1.6B
Cash$3.6B$3.3B$3.2B$2.8B
SEC XBRL, fiscal years, as known on 2026-10-28

TEVA Stock Sonar score 6/7 axes

Find similar shapesCompare

TEVA ranks highest on institutional and government (96th percentile) and profitability (68th), and lowest on insider conviction (3rd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
68
Inputs
  • Return on equity+9.7% · 85 pct, sector of 545
  • Return on assets+1.8% · 83 pct, sector of 691
  • Return on invested capital+4.2% · 16 pct, sector of 45
  • Return on capital employed+6.1% · 88 pct, sector of 576
Financial health
39
Inputs
  • Debt to equity4.30x · 4 pct, sector of 352
  • Cash flow to debt0.06x · 74 pct, sector of 371
Growth
51
Inputs
  • Revenue growth, YoY+4.3% · 51 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
3
Inputs
  • Net Form 4 buying (codes P and S), 180d-$35.9M · 6 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
96
Inputs
  • Funds adding, latest quarter366 · 96 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+2.7% · 69 pct, sector of 813
  • Recalls per $1B revenue, 3y1.80 per $1B · 19 pct, universe of 292
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+17.8% · 23 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TEVA filings, in plain words

Are Teva Pharmaceutical Industries insiders buying or selling TEVA?

In the 180 days to 2026-10-28, Teva Pharmaceutical Industries insiders were net sellers, a net $35.9M across purchases and sales reported on Form 4, by 14 sellers.

Are there planned insider sales of TEVA?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $16.7M of stock; the latest, by Savage Brian, was filed 2026-09-21.

Read the full summary

In the 180 days to 2026-10-28, Teva Pharmaceutical Industries insiders were net sellers of TEVA, a net $35.9M across purchases and sales reported on Form 4 by 14 sellers. None of the 21 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $16.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies